The latest data point for VEEV's diluted EPS in Q4'26 stands at 1.45 USD, reflecting a solid quarter-over-quarter increase from 1.40 USD in Q3'26 and marking the highest value in the observed period. Over the timeframe from Q1'24 to Q4'26, VEEV's diluted EPS has exhibited a consistent upward trend, rising from 0.81 USD to 1.45 USD, with an average quarterly growth of approximately 0.05 USD despite minor fluctuations, such as a dip to 0.68 USD in Q2'24. Year-over-year EPS growth has been predominantly positive, averaging around 25%, though it experienced a notable decline of -22.4% in Q4'24 before rebounding strongly with peaks like 52.9% in Q2'25, underscoring resilient profitability amid potential operational expansions in the healthcare IT sector.